We have tested several drugs targeting NF-κB2 and PKCδ, and found that both oridonin and AD198 exhibit potent anti-tumor activities on B cell neoplasms with TRAF3 deletions or inactivating mutations. Here, TRAF3 is linked to neoplasm.